Billiontoone (NASDAQ:BLLN) Issues Earnings Results

Key Points

• Q1 beat: BillionToOne reported EPS of $0.34 vs. $0.01 expected and revenue up ~84% YoY to $108.4M, delivering profitability, positive cash flow and $537M in cash with a 73% gross margin.
• Market access & guidance: The company is now in‑network with Anthem and UnitedHealthcare (≈300M contracted lives), saw ASPs rise 28% to $571, and raised 2026 revenue guidance to $450–$465M.
• Near‑term limits & mixed sentiment: New product Unity Confirm shows strong early concordance but currently addresses only ~0.5–1% of patients with a prospective study taking 1–3 years, accounts receivable have risen, and analysts remain mixed despite a consensus "Moderate Buy" and an average price target of $126.71.

Billiontoone (NASDAQ:BLLN - Get Free Report) released its earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.33, Zacks reports. The company's quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.39) earnings per share.

Here are the key takeaways from Billiontoone's conference call:

• Q1 financials were strong — revenue grew 84% YoY to $108.4M with 44% test volume growth, a 73% gross margin, 16% GAAP operating margin, and $537M cash, delivering profitability and positive cash flow.
• Market access and pricing momentum — BillionToOne is now in‑network with Anthem and UnitedHealthcare, reaching ~300 million contracted lives, and ASPs rose 28% YoY to $571, prompting raised 2026 revenue guidance to $450–$465M.
• Product differentiation — the launch of Unity Confirm, the company’s non‑invasive fetal cell–based confirmation assay, showed initial 100% concordance versus invasive diagnostics and is positioned to strengthen Unity as a frontline prenatal offering.
• Oncology ramp shows momentum (oncology revenue nearly 5x to $10.7M and tumor‑naive MRD on track), but longer‑term upside depends on achieving Medicare coverage for Northstar Response and scaling to improve oncology margins.
• Near‑term limits and risks — BillionToOne expects Unity Confirm to address only ~0.5–1% of patients (so minimal direct revenue), its prospective concordance study may take 1–3 years, and accounts receivable rose due to new payer contracts, which could affect short‑term cash conversion.

Billiontoone Trading Up 1.9%

Shares of NASDAQ BLLN traded up $1.50 during trading on Wednesday, reaching $81.40. The company had a trading volume of 716,203 shares, compared to its average volume of 473,833. Billiontoone has a 52 week low of $61.96 and a 52 week high of $138.70. The company has a current ratio of 11.69, a quick ratio of 11.32 and a debt-to-equity ratio of 0.12. The business's 50 day moving average is $77.51.

Analysts Set New Price Targets

Several research firms have commented on BLLN. Wells Fargo & Company lowered their target price on shares of Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 5th. Weiss Ratings restated a "sell (d)" rating on shares of Billiontoone in a research report on Friday, May 1st. Guggenheim decreased their price target on shares of Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, March 30th. Wall Street Zen upgraded shares of Billiontoone from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Finally, BTIG Research decreased their target price on shares of Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $126.71.

Institutional Investors Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quadrature Capital Ltd acquired a new position in Billiontoone during the fourth quarter valued at approximately $614,000. Ghisallo Capital Management LLC acquired a new position in Billiontoone during the fourth quarter valued at approximately $573,000. Alyeska Investment Group L.P. acquired a new position in Billiontoone during the fourth quarter valued at approximately $573,000. Walleye Capital LLC acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $488,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $477,000.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.